Roche assumes development of KSQ KSQ's USP1 inhibitor USP1 inhibitor for cancer

2023-07-13

交易

临床1期引进/卖出免疫疗法

Roche and KSQ Therapeutics have entered into a worldwide license and collaboration agreement for the development and commercialisation of KSQ-4279, which is being studied as a treatment for solid tumours, KSQ announced on Thursday. Roche will assume the development of the first-in-class, selective small molecule inhibitor of USP1, a protein regulating DNA damage response (DDR). Financial terms of the deal were not disclosed,

James Sabry, Roche global head of pharma partnering, said that "DDR is a promising and emerging area of research in oncology," adding that KSQ-4279 "is a potential new treatment option for patients with significant unmet medical needs across a range of cancers." KSQ chief executive Qasim Rizvi explained that KSQ-4279 "was discovered through our proprietary CRISPRomics platform," adding that "this agreement enables us to fully focus our attention on advancing our own immunotherapy programmes and to continue leveraging our successful platform to discover novel targets."

Under the agreement, KSQ will receive an upfront payment and will be eligible to receive additional milestone and royalty payments. Roche gains a global license and will be fully responsible for the further development of KSQ-4279 in 2024. KSQ-4279 is currently being studied in a Phase I dose-escalation and expansion trial in patients with advanced solid tumours, as a monotherapy and in combination.

In January, several research-stage DDR programmes uncovered by KSQ's CRISPRomics platform were acquired by Ono Pharmaceutical. In May, KSQ and Takeda expanded a 2021 collaboration to research and validate novel tumour-intrinsic targets.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构